TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Reached agreement with FDA on pivotal study design for TSC-101 following productive end of Phase 1 meetingData from ALLOHA™ Phase 1 heme trial to ...